70 citations
,
April 2016 in “Experimental Dermatology” In this study, oral tofacitinib treatment led to significant hair regrowth and changes in skin and blood biomarkers in a patient with alopecia areata.
April 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” This study demonstrated that the Alopecia Areata Disease Activity Index (ALADIN), a new biomarker, strongly correlates with treatment response in patients using JAK inhibitors for alopecia areata.
130 citations
,
February 2018 in “Journal of Investigative Dermatology” This study found that tofacitinib led to ≥50% hair regrowth in eight out of twelve patients with moderate to severe alopecia areata, suggesting a potential benefit for using JAK inhibitors in treating this condition.
November 2024 in “SKIN The Journal of Cutaneous Medicine” This study found that generic quality of life questionnaires, like the SF-36 and DLQI, are not sensitive enough to detect differences in health-related quality of life between patients with varying severity of alopecia areata.
October 2021 in “Dermatology Reports” This study found that serum IL-17A levels were significantly higher in patients with alopecia areata compared to healthy controls and correlated with disease severity and activity.
